UTHR UNITED THERAPEUTICS Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: UTHR

Price (delayed)

$544.33

Market cap

$23.11B

P/E Ratio

18.59

Dividend/share

N/A

EPS

$29.28

Enterprise value

$21.83B

?
Relative Growth: Rel. Growth: 80
Relative Strength: Rel. Strength: 72
Relative Valuation: Rel. Valuation: 53
Relative Profitability: Rel. Profitability: 95

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and ...

Highlights
The debt has plunged by 100% YoY
The company's revenue rose by 6% YoY
The company's EPS rose by 8% YoY but it fell by 2.8% QoQ
UNITED THERAPEUTICS's net income has increased by 6% YoY but it has decreased by 3.5% QoQ
The quick ratio has declined by 29% since the previous quarter and by 18% year-on-year
The stock's P/E is 28% above its 5-year quarterly average of 14.4 and 19% above its last 4 quarters average of 15.4
Sector: Healthcare
Industry: Biotechnology
Website: http://www.unither.com/
Peers: LLY GILD TEVA PFE

Key stats

What are the main financial stats of UTHR

UTHR stock price

How has the UNITED THERAPEUTICS stock price performed over time
Intraday
1.12%
1 week
-0.72%
1 month
-4.24%
1 year
90.07%
YTD
11.71%
QTD
-8.2%

Financial performance

How have UNITED THERAPEUTICS's revenue and profit performed over time
Revenue
$3.17B
Gross profit
$2.74B
Operating income
$1.44B
Net income
$1.29B
Gross margin
86.6%
Net margin
40.6%
The company's revenue rose by 6% YoY
UNITED THERAPEUTICS's net income has increased by 6% YoY but it has decreased by 3.5% QoQ
The operating income has contracted by 3.8% from the previous quarter but it has grown by 2.3% YoY
The company's gross profit rose by 3% YoY

Price vs fundamentals

How does UTHR's price correlate with its fundamentals

Growth

What is UNITED THERAPEUTICS's growth rate over time

Valuation

What is UNITED THERAPEUTICS stock price valuation
UTHR P/E details
P/E
18.59
P/B
4.04
P/S
7.47
EV/EBIT
13.43
EV/EBITDA
12.74
EV/Sales
6.89
The stock's P/E is 28% above its 5-year quarterly average of 14.4 and 19% above its last 4 quarters average of 15.4
The company's EPS rose by 8% YoY but it fell by 2.8% QoQ
UTHR's price to book (P/B) is 67% higher than its 5-year quarterly average of 2.4 and 33% higher than its last 4 quarters average of 3.0
The equity has declined by 17% since the previous quarter and by 13% year-on-year
The stock's P/S is 37% above its 5-year quarterly average of 5.4 and 17% above its last 4 quarters average of 6.3
The company's revenue rose by 6% YoY

Efficiency

How efficient is UNITED THERAPEUTICS business performance
The company's return on sales fell by 6% QoQ and by 3.9% YoY
The ROIC has contracted by 4.1% from the previous quarter and by 3.8% YoY
UNITED THERAPEUTICS's return on assets has increased by 3% YoY

Dividends

What is UTHR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for UTHR.

Financial health

How did UNITED THERAPEUTICS financials performed over time
The quick ratio has declined by 29% since the previous quarter and by 18% year-on-year
The current ratio has contracted by 27% from the previous quarter and by 12% YoY
The debt is 100% less than the equity
UNITED THERAPEUTICS's debt to equity has shrunk by 100% YoY
The debt has plunged by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.